Ibogaine Opioid Treatment Research: What 2025-2026 Studies Found
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal...
Executive Burnout Psychedelic Therapy: What the Research Shows
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce...
Psilocybin Alcohol Use Disorder: What Hopkins and NYU Research Found
Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days...
What executives are actually using psychedelic therapy for (and what the data shows)
Psychedelic therapy for executives is moving beyond reputation and into clinical evidence. A growing number of C-suite leaders are using professionally supported psilocybin and ketamine experiences...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.